Ibrutinib is a new targeted therapy for the treatment of Alzheimer’s disease. This drug, in combination with other drugs, seems to be effective in treating the symptoms of the disease.
Based on results of a pivotal study comparing FCR to an alternative rituximab-based therapy, patients receiving ibrutinib at https://www.aasraw.com/products/ibrutinib/ rituximab treatment had a remarkable two-thirds decrease in the risk of Alzheimer’s disease progression relative to patients receiving usual care.
Overall survival was also improved for patients getting ibrutinib treatment compared to those receiving usual care. However, the drug has not yet been approved by the FDA for this use.
Ibrutinib is a novel anticancer agent and thus its mechanism of action is still being studied extensively. It has been used in the treatment of various cancers including breast, prostate, ovarian, cervical, kidney, pancreatic, Hodgkin’s disease and metastatic colorectal cancer.
It is also applied to treat various non-cancerous tumors and to …Read more